CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Strength||25 mg/mL & 50 mg/vial|
|Indication||Renal Cell Carcinoma|
|Funding Request||For the treatment of patients with advanced renal cell carcinoma (RCC) in combination with axinitib, as first-line treatment.|
|Pre Noc Submission||Yes|
|NOC Date||December 13, 2019|
|Submission Date||August 2, 2019|
|Submission Deemed Complete||August 19, 2019|
|Stakeholder Input Deadline ‡||August 19, 2019|
|Check-point meeting||October 30, 2019|
|pERC Meeting||January 16, 2020|
|Initial Recommendation Issued||January 30, 2020|
|Feedback Deadline ‡||February 13, 2020|
|pERC Reconsideration Meeting||March 19, 2020|
|Final Recommendation Issued||April 2, 2020|
|Notification to Implement Issued||April 20, 2020|
|Therapeutic Area||Renal Cell Carcinoma (RCC)|
|Recommendation Type||Reimburse with clinical criteria and/or conditions|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.